Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Teva Pharmaceutical Industries Ltd. resumes trading today in Tel Aviv at the biggest discount to New York in 2 1/2 years after the prospect of acquisitions among generic-drug makers fueled gains in its U.S.-traded stock.
Boston Scientific Corp.’s Watchman improved survival in patients with erratic heart rates after four years, an unexpected finding that may help create a $500 million market, said Chief Executive Officer Michael Mahoney.
Jauyo Lee, a former investment banker with Leerink Swann LLC, pleaded guilty to providing inside information about impending mergers involving clients to a college friend who traded on the tips, the U.S. said.
Edwards Lifesciences Corp., the biggest-maker of aortic heart valves implanted with a catheter, plunged the most in a dozen years after the company cut its 2013 forecast on slower-than-anticipated sales.